Tabelecleucel
Tabelecleucel is a bank of donor T cells trained against Epstein-Barr virus, approved in Europe in 2022 as the first off-the-shelf T-cell therapy, for EBV-driven lymphoma after transplant when rituximab has failed.
Overview
Atara Biotherapeutics built tabelecleucel from EBV-specific T-cell lines of healthy donors, selected for each patient by shared HLA alleles, so no manufacturing from the patient's own cells is needed. The European Commission approved it in December 2022 as Ebvallo for relapsed or refractory EBV-positive post-transplant lymphoproliferative disease after at least one prior therapy, the first allogeneic T-cell immunotherapy approved anywhere; the FDA issued a complete response letter in 2024 over manufacturing questions. Pierre Fabre markets it and runs trials in other EBV-associated diseases.
T cells from healthy donors expanded against Epstein-Barr virus antigens and matched to the patient by HLA restriction; infused, they kill EBV-infected lymphoma cells.
1.Tabelecleucel slips into a pocket on its target.
Approvals
| Region | Year | Indication |
|---|---|---|
| EU | 2022 | Relapsed or refractory EBV-positive post-transplant lymphoproliferative disease after at least one prior therapy |
Trials
topTrials recruiting now
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Landmark trials
Latest papers
topQuery for this drug: (TITLE:"Tabelecleucel" OR ABSTRACT:"Tabelecleucel" OR TITLE:"Ebvallo" OR ABSTRACT:"Ebvallo" OR TITLE:"ATA129" OR ABSTRACT:"ATA129" OR TITLE:"tab-cel" OR ABSTRACT:"tab-cel") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Tabelecleucel, not a curated reading list.